156 related articles for article (PubMed ID: 31521828)
41. Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis.
Petek-Balcı B; Çoban A; Shugaiv E; Türkoğlu R; Ulusoy C; İçöz S; Pehlivan M; Tüzün E; Akman-Demir G; Kürtüncü M; Eraksoy M
Int J Neurosci; 2015 May; 125(5):352-6. PubMed ID: 25026220
[TBL] [Abstract][Full Text] [Related]
42. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
[TBL] [Abstract][Full Text] [Related]
43. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.
Lanzillo R; Carbone F; Quarantelli M; Bruzzese D; Carotenuto A; De Rosa V; Colamatteo A; Micillo T; De Luca Picione C; Saccà F; De Rosa A; Moccia M; Brescia Morra V; Matarese G
Clin Immunol; 2017 Oct; 183():249-253. PubMed ID: 28823971
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
45. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
46. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
[TBL] [Abstract][Full Text] [Related]
47. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.
Wencel-Warot A; Michalak S; Warot M; Kalinowska-Lyszczarz A; Kazmierski R
Medicine (Baltimore); 2016 Nov; 95(45):e5337. PubMed ID: 27828855
[TBL] [Abstract][Full Text] [Related]
48. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
49. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE; Zhao Z; Stebbins CC; Cadavid D; Buko AM; Whalley ET; Davis JA; Versage EM; Richert JR; Axtell RC; Steinman L; Medori R
Neurology; 2012 Aug; 79(6):531-7. PubMed ID: 22573631
[TBL] [Abstract][Full Text] [Related]
50. Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
Al-Iedani O; Lea R; Ribbons K; Ramadan S; Lechner-Scott J
J Neuroimaging; 2022 Nov; 32(6):1109-1120. PubMed ID: 35922880
[TBL] [Abstract][Full Text] [Related]
51. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
52. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.
Acar NP; Tuncer A; Ozkazanc D; Ozbay FG; Karaosmanoglu B; Goksen S; Sayat G; Taskiran EZ; Esendagli G; Karabudak R
J Neuroimmunol; 2020 Oct; 347():577353. PubMed ID: 32745802
[TBL] [Abstract][Full Text] [Related]
53. Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment.
Zhukovsky C; Herman S; Wiberg A; Cunningham JL; Kultima K; Burman J
Acta Neurol Scand; 2021 Jun; 143(6):602-607. PubMed ID: 33626181
[TBL] [Abstract][Full Text] [Related]
54. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L
Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333
[TBL] [Abstract][Full Text] [Related]
55. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
Zhang X; Hay JW; Niu X
CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
[TBL] [Abstract][Full Text] [Related]
58. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
60. Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.
Borriello G; Pozzilli C
Neurol Sci; 2021 May; 42(Suppl 1):29-36. PubMed ID: 33751260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
